All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Kura Oncology's Komzifti (ziftomenib) receives FDA approval for NPM1-mutant acute myeloid leukemia treatment
Small molecule, cancer, menin inhibitor, acute myeloid leukemia, NPM1 mutation - Read more

THE GOOD
Business Development & Partnerships

Third Arc Bio, Adagene partner on cancer T cell engagers using SAFEbody technology, $5M upfront, $840M milestones
Licensing deal, oncology, T cell engager, milestone payments, royalties - Read more

Mursla Bio partners with global pharma on AI precision medicine platform for MASH biomarker development
Research collaboration, AI/ML, biomarker development, precision medicine, diagnostics - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Gilead's bictegravir/lenacapavir combination achieves Ph3 non-inferiority for HIV treatment in virologically suppressed adults
Small molecule, infectious disease, HIV integrase inhibitor, HIV, combination therapy - Read more

Eisai presents 48-month lecanemab data showing sustained benefits in early Alzheimer's disease patients
Antibody, neurological, monoclonal antibody, Alzheimer disease, amyloid beta, apolipoprotein E - Read more

THE GOOD
Fundraises

T-Therapeutics raises $91M Series A extension, advancing TCR-CD3 bispecifics for cancer/autoimmune
Oncology, autoimmune, TCR therapeutics, bispecifics, preclinical - Read more

4TEEN4 raises €55M ($63.75M) Series C for cardiogenic shock antibody procizumab development
Cardiovascular, antibody, clinical-stage, critical care - Read more

Gate Bioscience raises $65M Series B, developing oral "molecular gates" eliminating disease proteins
Small molecule, protein degradation, inflammatory diseases, neurology, platform technology, preclinical - Read more

Scripta Therapeutics raises $12M seed, transcription factor-targeting disease-modifying drug discovery
Transcription factor modulation, AI/ML platform, drug discovery, platform technology - Read more

Ladder Bio raises $5.5M Series Seed, developing Spiroligomer peptide-like therapeutics platform
Platform technology, peptide therapeutics, oral bioavailability, preclinical - Read more

Modulight Biotherapeutics raises $12M Seed, optogenetic platform for neurological disorders
Neurological, optogenetic platform, gene therapy, preclinical - Read more

THE GOOD
Investments

Boryung breaks ground on penicillin plant expansion, doubling production capacity in South Korea
Antibiotic, infectious disease, operational, capacity expansion - Read more

THE GOOD
Mergers & Acquisitions

Pfizer officially closes $9.2 billion Metsera acquisition after winning bidding war against Novo Nordisk
GLP-1 receptor agonist, obesity, strategic, major transaction - Read more

Day One acquires struggling ADC developer Mersana for $129M upfront in milestone-heavy deal
Antibody-drug conjugate, oncology, strategic, major transaction - Read more

THE GOOD
Politics & Policy

Merck KGaA continues White House tariff exemption talks weeks after announcing pricing deal
IVF treatment, reproductive health, regulatory, financial - Read more [Paywall]

THE BAD
Business Development & Partnerships

Eli Lilly, Novo Nordisk deny Mangoceuticals' false partnership claims for obesity drug access programs
GLP-1 receptor agonist, obesity, competitive, operational - Read more

THE BAD
Clinical Trials

Korro Bio abandons lead RNA editing drug KRRO-110 after disappointing Ph1 results in alpha-1 antitrypsin deficiency
RNA editing, genetic disorder, AATD, alpha-1 antitrypsin deficiency, delivery system - Read more

THE BAD
Strategic Plans

Century Therapeutics discontinues CNTY-101 Ph1/2 trial for B cell-mediated autoimmune diseases to conserve cash
Cell therapy, autoimmune, CAR-T, bispecific antibody, prostate cancer, pancreatic cancer - Read more

Zealand pauses mid-stage obesity drug dapiglutide to focus on partnered survodutide and petrelinitide programs
GLP-1 receptor agonist, obesity, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here